BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Agopian VG, Morshedi MM, Mcwilliams J, Harlander-locke MP, Markovic D, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Hiatt JR, Busuttil RW. Complete Pathologic Response to Pretransplant Locoregional Therapy for Hepatocellular Carcinoma Defines Cancer Cure After Liver Transplantation: Analysis of 501 Consecutively Treated Patients. Annals of Surgery 2015;262:536-45. [DOI: 10.1097/sla.0000000000001384] [Cited by in Crossref: 77] [Cited by in F6Publishing: 86] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Shimada S, Shamaa T, Ivanics T, Kitajima T, Adhnan M, Collins K, Rizzari M, Yoshida A, Abouljoud M, Salgia R, Nagai S. Multiple Pretransplant Treatments for Patients Without Pathological Complete Response may Worsen Posttransplant Outcomes in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2022. [DOI: 10.1245/s10434-022-12789-2] [Reference Citation Analysis]
2 Minoux K, Lassailly G, Ningarhari M, Lubret H, El Amrani M, Canva V, Truant S, Mathurin P, Louvet A, Lebuffe G, Goria O, Nguyen-khac E, Boleslawski E, Dharancy S. Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation. Transpl Int 2022;35. [DOI: 10.3389/ti.2022.10569] [Reference Citation Analysis]
3 Núñez KG, Sandow T, Lakey MA, Fort D, Cohen AJ, Thevenot PT. Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy. Front Oncol 2022;12:809860. [DOI: 10.3389/fonc.2022.809860] [Reference Citation Analysis]
4 Benkö T, König J, Theysohn JM, Schotten C, Saner FH, Treckmann J, Radunz S. Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization? Eur J Med Res 2022;27:74. [PMID: 35619164 DOI: 10.1186/s40001-022-00708-w] [Reference Citation Analysis]
5 Seehofer D, Petrowsky H, Schneeberger S, Vibert E, Ricke J, Sapisochin G, Nault J, Berg T. Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation—Adjusting the Odds? Transpl Int 2022;35:10333. [DOI: 10.3389/ti.2022.10333] [Reference Citation Analysis]
6 Ahmed O, Vachharajani N, Croome KP, Tabrizian P, Agopian V, Halazun K, Hong JC, Dageforde LA, Chapman WC, Doyle MM; Primary Liver Tumor Study Group. Are Current National Review Board Downstaging Protocols for Hepatocellular Carcinoma Too Restrictive? J Am Coll Surg 2022;234:579-88. [PMID: 35290278 DOI: 10.1097/XCS.0000000000000140] [Reference Citation Analysis]
7 Pitkevich AA, Kosyrev VY, Dzhanyan IA, Novruzbekov MS, Monakhov AR, Zubenko SI, Voskanyan SE, Rudakov VS, Moroz EA, Breder VV. Neoadjuvant therapy bridging patients with hepatocellular cancer waiting for liver transplant. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-20-110-116] [Reference Citation Analysis]
8 Crocetti L, Bozzi E, Scalise P, Bargellini I, Lorenzoni G, Ghinolfi D, Campani D, Balzano E, De Simone P, Cioni R. Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation. Cancers (Basel) 2021;13:5558. [PMID: 34771720 DOI: 10.3390/cancers13215558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lin J, Li X, Shi X, Zhang L, Liu H, Liu J, Wang K, Shen F. Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Transl Med 2021;9:1130. [PMID: 34430571 DOI: 10.21037/atm-21-1120] [Reference Citation Analysis]
10 Ward EM, Sherif AE, O'Neill S, Hughes M, Ireland H, Wigmore SJ, Adair A. Clinical Outcomes of Ablation Compared with Resection for Single Hepatocellular Carcinoma Lesions, as a Primary Treatment or Bridging to Liver Transplantation: A Retrospective Comparative Study. Ann Transplant 2021;26:e931980. [PMID: 34326301 DOI: 10.12659/AOT.931980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021; 13(5): 392-405 [PMID: 34122730 DOI: 10.4240/wjgs.v13.i5.392] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
12 Mastrocostas K, Fischer S, Munoz-Schuffenegger P, Jang HJ, Dawson LA, Liu ZA, Sapisochin G, Kim TK. Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation. Abdom Radiol (NY) 2021;46:1572-85. [PMID: 33074426 DOI: 10.1007/s00261-020-02821-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Gül-Klein S, Kästner A, Haber PK, Krenzien F, Wabitsch S, Krannich A, Andreou A, Eurich D, Tacke F, Horst D, Pratschke J, Schmelzle M. Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections. J Hepatocell Carcinoma 2021;8:133-43. [PMID: 33777855 DOI: 10.2147/JHC.S292010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
15 Marinelli B, Cedillo M, Pasik SD, Charles D, Murthy S, Patel RS, Fischman A, Ranade M, Bishay V, Nowakowski S, Sung M, Marron T, Lookstein R, Schwartz M, Kim E. Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. J Vasc Interv Radiol 2020;31:1729-1738.e1. [PMID: 33012649 DOI: 10.1016/j.jvir.2020.07.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
16 Chandra P, Nath S, Jain D. Complete Pathological Response Noted in Explanted Liver After Y90-SIR-Spheres Therapy for Hepatocellular Carcinoma. Indian J Nucl Med 2020;35:267-8. [PMID: 33082694 DOI: 10.4103/ijnm.IJNM_23_20] [Reference Citation Analysis]
17 Baimas-George M, Watson M, Sulzer J, Salibi P, Murphy KJ, Levi D, Martinie JB, Vrochides D, Baker EH, Ocuin L, Iannitti DA. Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation. Surg Endosc 2021;35:3122-30. [PMID: 32588344 DOI: 10.1007/s00464-020-07747-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bajwa R, Madoff DC, Kishore SA. Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. Dig Dis Interv 2020;4:134-47. [PMID: 32832829 DOI: 10.1055/s-0040-1712146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bauschke A, Altendorf-Hofmann A, Ardelt M, Kissler H, Tautenhahn HM, Settmacher U. Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. J Cancer Res Clin Oncol 2020;146:1819-27. [PMID: 32356179 DOI: 10.1007/s00432-020-03215-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
20 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
21 Cools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma. Liver Transpl 2020;26:203-14. [PMID: 31677319 DOI: 10.1002/lt.25673] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
22 Herreras J, Di Maira T, Vinaixa C, San Juan F, Rubín Á, Berenguer M. Milan-out Criteria and Worse Intention-to-Treat Outcome Postliver Transplantation. Transplant Direct 2019;5:e487. [PMID: 31723582 DOI: 10.1097/TXD.0000000000000934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Chuang YH, Ou HY, Yu CY, Chen CL, Weng CC, Tsang LL, Hsu HW, Lim WX, Huang TL, Cheng YF. Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation. Cancer Imaging 2019;19:74. [PMID: 31730015 DOI: 10.1186/s40644-019-0264-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Zhang W, Xu AH, Wang W, Wu YH, Sun QL, Shu C. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation. BMC Cancer 2019;19:1041. [PMID: 31690274 DOI: 10.1186/s12885-019-6265-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
25 Grąt M, Krawczyk M, Stypułkowski J, Morawski M, Krasnodębski M, Wasilewicz M, Lewandowski Z, Grąt K, Patkowski W, Zieniewicz K. Prognostic Relevance of a Complete Pathologic Response in Liver Transplantation for Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:4556-65. [PMID: 31520204 DOI: 10.1245/s10434-019-07811-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Bale R, Schullian P, Eberle G, Putzer D, Zoller H, Schneeberger S, Manzl C, Moser P, Oberhuber G. Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers. Hepatology 2019;70:840-50. [PMID: 30520063 DOI: 10.1002/hep.30406] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
27 Kim DG, Lee JG, Joo DJ, Kim SI, Kim MS. Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation. Sci Rep 2019;9:10386. [PMID: 31316165 DOI: 10.1038/s41598-019-46871-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
28 Welling TH, Eddinger K, Carrier K, Zhu D, Kleaveland T, Moore DE, Schaubel DE, Abt PL. Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation. Liver Transpl. 2018;24:1233-1242. [PMID: 29729113 DOI: 10.1002/lt.25194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
29 Eilard MS, Andersson M, Naredi P, Geronymakis C, Lindnér P, Cahlin C, Bennet W, Rizell M. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer 2019;19:568. [PMID: 31185950 DOI: 10.1186/s12885-019-5760-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
30 Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant 2019;19:2210-8. [PMID: 30861298 DOI: 10.1111/ajt.15353] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
31 Sangiovanni A, Colombo M. Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it? Hepatobiliary Surg Nutr 2018;7:202-5. [PMID: 30046574 DOI: 10.21037/hbsn.2018.03.12] [Reference Citation Analysis]
32 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
33 Manzia TM, Lai Q, Iesari S, Perera MTPR, Komuta M, Carvalheiro A, Shah T, Angelico R, Quaranta C, Nicolini D, Montalti R, Scarpelli M, Palmieri G, Orlacchio A, Vivarelli M, Angelico M, Lerut J, Tisone G. Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study. Transpl Int 2018. [PMID: 29572974 DOI: 10.1111/tri.13153] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
34 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol 2018; 10(2): 308-318 [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
35 Shaker MK, Montasser IF, Sakr M, Elgharib M, Dabbous HM, Ebada H, Dorry AE, Bahaa M, Meteini ME. Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt. J Hepatocell Carcinoma 2018;5:29-36. [PMID: 29520343 DOI: 10.2147/JHC.S147098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
36 Tan CHN, Yu Y, Tan YRN, Lim BLK, Iyer SG, Madhavan K, Kow AWC. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere? Ann Hepatobiliary Pancreat Surg 2018;22:27-35. [PMID: 29536053 DOI: 10.14701/ahbps.2018.22.1.27] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
37 Clouston AD, Hübscher SG. Transplantation Pathology. Macsween's Pathology of the Liver 2018. [DOI: 10.1016/b978-0-7020-6697-9.00014-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206-1213. [PMID: 29068145 DOI: 10.1111/ajt.14549] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
39 Colombo M, Torzilli G. Expanding transplantation of patients with a liver cancer without harming allocation: a priority in the era of scarce donation. Hepatobiliary Surg Nutr 2017;6:339-41. [PMID: 29152483 DOI: 10.21037/hbsn.2017.05.13] [Reference Citation Analysis]
40 Agopian VG, Chapman WC, Busuttil RW; United States Multicenter Hepatocellular Carcinoma Transplant Consortium (UMHTC). Response: "Which is the True Role of Bridging Therapies for HCC Patients Waiting for Liver Transplantation?". Ann Surg 2018;268:e57-60. [PMID: 29064906 DOI: 10.1097/SLA.0000000000002577] [Reference Citation Analysis]
41 Zhang T, Liu Y, Peng X, Fan J, Peng Z. Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation. Dis Markers 2017;2017:1754696. [PMID: 29162948 DOI: 10.1155/2017/1754696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg. 2017;402:863-871. [PMID: 28755240 DOI: 10.1007/s00423-017-1609-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
43 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
44 Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, Russo M, Beecroft R, Ghanekar A, Bhat M, Brierley J, Greig PD, Knox JJ, Dawson LA, Grant DR. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9. [PMID: 28257902 DOI: 10.1016/j.jhep.2017.02.022] [Cited by in Crossref: 149] [Cited by in F6Publishing: 160] [Article Influence: 29.8] [Reference Citation Analysis]
45 Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, McWilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DSK. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. Hepatology 2017;65:1979-90. [PMID: 28170115 DOI: 10.1002/hep.29098] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 12.4] [Reference Citation Analysis]
46 Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017;23:3690-701. [PMID: 28611522 DOI: 10.3748/wjg.v23.i20.3690] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
47 Zaydfudim VM, Vachharajani N, Klintmalm GB, Jarnagin WR, Hemming AW, Doyle MB, Cavaness KM, Chapman WC, Nagorney DM. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016;264:650-8. [PMID: 27433910 DOI: 10.1097/SLA.0000000000001866] [Cited by in Crossref: 41] [Cited by in F6Publishing: 49] [Article Influence: 8.2] [Reference Citation Analysis]
48 Kishore S, Friedman T, Madoff DC. Update on Embolization Therapies for Hepatocellular Carcinoma. Curr Oncol Rep 2017;19:40. [PMID: 28421483 DOI: 10.1007/s11912-017-0597-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
49 Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017;3:493-500. [PMID: 27838698 DOI: 10.1001/jamaoncol.2016.5116] [Cited by in Crossref: 159] [Cited by in F6Publishing: 178] [Article Influence: 31.8] [Reference Citation Analysis]
50 Ho MH, Chen TW, Ou KW, Yu JC, Hsieh CB. Rescue strategy for advanced liver malignancy with retrohepatic inferior vena cava thrombi: experience to promote surgical oncological benefit. World J Surg Oncol 2017;15:83. [PMID: 28403878 DOI: 10.1186/s12957-017-1145-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
51 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 210] [Cited by in F6Publishing: 229] [Article Influence: 42.0] [Reference Citation Analysis]
52 Kashkoush S, Saleh S, Elmoghazy W. Serum Alpha-Fetoprotein as a Biomarker in Liver Transplantation. Biomarkers in Disease: Methods, Discoveries and Applications 2017. [DOI: 10.1007/978-94-007-7675-3_34] [Reference Citation Analysis]
53 Beal EW, Dittmar KM, Hanje AJ, Michaels AJ, Conteh L, Davidson G, Black SM, Bloomston PM, Dillhoff ME, Schmidt CR. Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival. Front Oncol 2016;6:143. [PMID: 27379205 DOI: 10.3389/fonc.2016.00143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
54 Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology 2016;63:1707-17. [PMID: 26703761 DOI: 10.1002/hep.28420] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 13.8] [Reference Citation Analysis]
55 Hibi T, Itano O, Shinoda M, Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today 2017;47:403-15. [PMID: 27130463 DOI: 10.1007/s00595-016-1337-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
56 Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol 2016; 22(12): 3325-3334 [PMID: 27022214 DOI: 10.3748/wjg.v22.i12.3325] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
57 Györi G, Clavien P, Lesurtel M. Liver Transplantation for Hepatocellular Carcinoma. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_32] [Reference Citation Analysis]
58 Kashkoush S, Saleh S, Elmoghazy W. Serum Alpha-Fetoprotein as a Biomarker in Liver Transplantation. Biomarkers in Disease: Methods, Discoveries and Applications 2016. [DOI: 10.1007/978-94-007-7742-2_34-1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]